Speaker Profile
Biography
Dr. Edward Kai-Hua Chow is CSO and Co-Founder of KYAN Technologies and a Fellow of the Royal Society of Chemistry. He was previously an Associate Professor in the Department of Pharmacology and Associate Director in the Cancer Science Institute of Singapore at National University of Singapore (NUS). He was also the Research Director for the Institute of Digital Medicine (WisDM). His research has focused on understanding how to treat specific oncology patients or cancer subtypes as well as the oncogenic drivers that determine subtype-specific therapy by applying engineering-based analytics towards personalised and precision drug combination design and ranking. He has published over 90 peer-reviewed papers with more than 11,000 citations. More importantly, his research has been commercially implemented in the clinic to provide better treatment solutions for cancer patients through KYAN’s MOH-licensed, CAP/CLIA clinical laboratory since 2023.
Talk
Personalizing Cancer Treatment Through Functional Combination Testing
Optim.AI combines live tumor testing and small-data AI to rank personalized drug combinations. This presentation highlights prospective clinical studies in lymphoma, AML, and solid tumors, alongside emerging immunotherapy applications using high-content imaging. Finally, we outline KYAN’s strategy to scale Optim.AI and expand global access to functional precision oncology.
AI for Clinical Decision Support Systems Showcase:
KYAN Technologies
KYAN Technologies develops functional precision medicine for cancer care and drug development. Its Optim.AI platform combines live tumor experiments with small-data AI to rank personalized drug combinations, helping oncologists evaluate treatment options and researchers prioritize combination therapies.
Session Abstract – PMWC 2027 Silicon Valley
The PMWC 2027 AI for Clinical Decision Support Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
Day 1 / Wed · Jan 27
Day 2 / Thu · Jan 28
Day 3 / Fri · Jan 29
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
